for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Smith & Nephew plc

SN.L

Latest Trade

1,667.50GBp

Change

-162.00(-8.85%)

Volume

6,623,284

Today's Range

1,648.50

 - 

1,780.50

52 Week Range

1,242.50

 - 

1,998.40

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,829.50
Open
1,780.00
Volume
6,623,284
3M AVG Volume
40.86
Today's High
1,780.50
Today's Low
1,648.50
52 Week High
1,998.40
52 Week Low
1,242.50
Shares Out (MIL)
874.69
Market Cap (MIL)
15,898.99
Forward P/E
23.53
Dividend (Yield %)
--

Next Event

Q3 2019 Smith & Nephew PLC Trading Statement Release

Latest Developments

More

Smith & Nephew Says FY Underlying Revenue Growth Guidance Range Raised 50 BPS To 3.0% To 4.0%

Smith & Nephew Launches Conquest FN Femoral Neck Fracture System

Smith & Nephew's Q1 Revenue Rises To $1.2 Bln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Smith & Nephew plc

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Industry

Medical Equipment & Supplies

Contact Info

Building 5, Croxley Park, Hatters Lane

+44.20.74017646

http://www.smith-nephew.com/

Executive Leadership

Roberto Quarta

Non-Executive Independent Chairman of the Board

Namal Nawana

Chief Executive Officer, Executive Director

Graham Baker

Chief Financial Officer, Executive Director

Rodrigo Bianchi

Interim President - Asia Pacific

Brad Cannon

President - Sports Medicine & ENT

Key Stats

2.62 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

4.7K

2017

4.8K

2018

4.9K

2019(E)

5.1K
EPS (USD)

2016

0.830

2017

0.950

2018

1.010

2019(E)

1.009
Price To Earnings (TTM)
29.58
Price To Sales (TTM)
4.17
Price To Book (MRQ)
4.17
Price To Cash Flow (TTM)
17.89
Total Debt To Equity (MRQ)
44.00
LT Debt To Equity (MRQ)
39.98
Return on Investment (TTM)
10.02
Return on Equity (TTM)
8.38

Latest News

Latest News

Smith+Nephew CEO steps down over pay, ex-Roche Diagnostics chief to take over

Smith+Nephew Plc <SN.L> Chief Executive Namal Nawana is stepping down after just 17 months in the role after becoming dissatisfied with his salary at the medical device maker.

Nivea-maker Beiersdorf launches brand for tattooed skin

German consumer goods firm Beiersdorf <BEIG.DE> is launching its first new brand for more than 30 years - a line of body creams specially for tattooed skin - as it seeks to tap into the growing popularity of skin art and appeal to a younger audience.

BRIEF-Dantax Receives Tender Offer For Its Shares In Opus Acoustics And Ansuz-Acoustics

* SAID ON THURSDAY RECEIVED TENDER OFFER FOR ALL ITS SHARES IN ASSOCIATED COMPANIES, OPUS ACOUSTICS AND ANSUZ-ACOUSTICS

Nivea-maker Beiersdorf buys Coppertone for $550 million

Beiersdorf, the maker of Nivea and other skin care brands, is buying U.S. sun care brand Coppertone from Bayer for $550 million to strengthen its position in North America, the German consumer goods firm said on Monday.

Smith & Nephew lifts revenue view after best quarter since 2015

Smith & Nephew nudged up its annual revenue growth forecast on Thursday after the medical products maker reported its best quarter in more than three years on increased demand from newer markets, sending its shares up 3.5 percent.

Smith & Nephew boosts full-year outlook after Q1 growth

Medical products maker Smith & Nephew on Thursday forecast annual revenue growth at the top half of its previously estimated range after reporting a 4.4 percent rise in quarterly revenue on an underlying basis.

Nivea revamp boosts Beiersdorf's sales

German consumer goods firm Beiersdorf reported a recovery in sales of its Nivea skin cream and its premium La Prairie brand in the first quarter after a new chief executive pledged more investment to fight niche brands.

Nivea-maker Beiersdorf reports strong first quarter

German consumer goods firm Beiersdorf reported a strong start to the year on Tuesday on healthy sales of its Nivea skin cream after its new chief executive launched a new strategy to help the firm compete with niche brands.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Smith & Nephew to buy Osiris in regenerative products push

Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million (500.4 million pounds), as the British medical products maker looks to bulk up in an area that is quickly growing.

Smith & Nephew to buy Osiris Therapeutics for $660 mln

British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as it looks to boost profit margins and find new sources of growth.

Smith & Nephew in talks to buy NuVasive for over $3 billion - FT

Britain's Smith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion (£2.3 billion), the Financial Times reported on Friday, citing people familiar with the talks.

UPDATE 1-Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

Emerging markets to fuel Smith & Nephew revenue growth in 2019

British medical products maker Smith & Nephew forecast full-year revenue growth in line with analysts' expectations on Thursday, as it looks to grow in emerging markets and expand its product line-up.

Smith & Nephew misses on Q4 revenue as developed markets slow

British medical products maker Smith & Nephew fell short of analysts' expectations for fourth-quarter revenue on Thursday, as growth in established markets including the United States slowed and the company was hurt by a stronger dollar.

U.S. FDA removes safety warning from Smith & Nephew's diabetic gel

British medical products maker Smith & Nephew said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved the removal of a safety warning on its treatment for lower extremity diabetic neuropathic ulcers.

Demand for new hips to boost Smith & Nephew profit margin

Britain's Smith & Nephew <SN.L> expects its trading profit margin to be higher this year than last on a better performance for its hips franchise, boosting its shares.

Smith & Nephew on track to meet guidance after Q3 revenue grows

British medical products maker Smith & Nephew said it was on track to meet full-year guidance after growing quarterly revenues by 3 percent, on strong demand for its artificial hips and knees in the United States and emerging markets.

Smith & Nephew buoyed by recovery in U.S. market

Smith & Nephew's new chief executive confirmed the company's full-year guidance on Thursday after improvement in its U.S. market helped revenues for the artificial hip and knee maker to recover from a tough start to the year.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up